Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

Let's continue. Novo Nordisk's semaglutide franchise consists of Ozempic, Rybelsus, and Victoza, whose sales totaled about DKK 40.77 billion in the last three months of 2024, up 15.6% quarter-on ...

For Novo Nordisk, a company still rooted in principles ... Leading its current growth is Victoza, a GLP-1 injectable which is used by type 2 diabetes patients, and which now outsells its biggest ...

Victoza, produced by Novo Nordisk, holds FDA approval for regulating blood sugar levels among individuals diagnosed with type ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Finally, a 2021 study funded by Novo Nordisk (the manufacturer of Victoza and Saxenda) found that combining liraglutide and exercise led to more weight loss than either treatment alone.

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...

REUTERS Other GLP-1 medications include Ozempic, Wegovy, Victoza, Saxenda, all made by Novo Nordisk. Fetterman noted that GLP ...